Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY24 Earnings Presentation
24 slides from Alembic Pharmaceuticals's earnings presentation, Nov 7, 2023
Slide 1: Exchange filing cover letter
Date: 7th November, 2023 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573
Slide 2: Investor Presentation Q2 and H1FY24
Alembic Pharmaceuticals Limited Investor Presentation Q2 and H1FY24 Nov 7, 2023
Slide 3: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 4: Quarterly Snapshot
Quarterly Snapshot INR Bn Key Highlights : 8% YoY Revenue R&D India Branded Business : India Branded Business recorded 5% growth with topline of Rs 5.77 Bn for Q2 15.95 7% QoQ 8% of Sales FY24. US Generics : Growth of 14% on sequential basis is driven by new launches and market share gain in few -6%
Slide 5: India branded business driving growth
India branded business driving growth INR Bn Business Q2 FY24 Q2 FY23 Y-o-Y Q1FY24 Q-o-Q H1 FY24 H1 FY23 Y-o-Y Formulations India 5.77 5.49 5% 5.24 10% 11.01 10.29 7% US 4.44 4.18 6% 3.90 14% 8.34 7.85 6% Ex-US 2.52 2.15 17% 2.66 -5% 5.18 3.96 31% API 3.22 2.94 10% 3.05 5% 6.28 5.27 19% Total Revenu
Slide 6: Diversified Therapy Presence
Diversified Therapy Presence Revenue- Q2 FY 24 Revenue- H1 FY 24 INR Bn INR Bn Growth: 5% CAGR: 9% 5.49 5.77 12.00 11.01 Vet 11.00 9.89 10.29 0.74 0.98 10.00 Acute 9.00 1.86 1.71 Specialty 8.00 7.15 7.15 7.21 7.00 2.88 3.07 6.00 5.00 4.00 Q2FY23 Q2FY24 H1FY19 H1FY20 H1FY21 H1FY22 H1FY23 H1FY24 Sales
Slide 7: Branded Business – Rx driven rankings
Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS BRANDS Q2 FY 24* Q2 FY 24 Q2 FY 24* Q2 FY 24 129.2 0.22 49 AZITHRAL 1 31.6 CLOFF 3 14.3 ROXID 1 94.6 WIKORYL 3 10.2 MAT Sept 23 ALTHROCIN 1 87.6 I
Slide 8: High focus therapies outgrowing market
High focus therapies outgrowing market ➢ Performed relatively better than the market in Antibiotic and Respiratory segments. Underlying factors remain strong despite exceptional under-performance of the market due to unique circumstances in the quarter. ➢ Gynecology and Gastro segments demonstrated
Slide 9: New Launches
New Launches New launches continue to do well along with promising future launches in H2 across key segments. Q2 FY24 Therapy Molecule Brands Launch INR Mn Gynecology Dydrogesterone ISOFIT 2022 151 ULGERAFT 2022 50 Raft Mkt Gastrointestinal EXCERAFT 2022 10 Esomeprazole ESOLEMBIC D 2022 40 Vildaglip
Slide 10: Animal Health Business
Animal Health Business Revenue- Q2 FY24 Revenue- H1 FY24 INR Mn INR Mn Growth 32% CAGR 18% 1780 1460 Q2FY23 1170 Q2FY24 980 880 740 760 770 Q2FY23 Q2FY24 H1FY19 H1FY20 H1FY21 H1FY22 H1FY23 H1FY24 Sales Mix- Q2 FY24 ➢ Operating in Livestock and Poultry market Antibiotic ➢ Established new division wit
Slide 11: Technology transforming business
Technology transforming business ➢ Deployment of CLM (closed loop marketing) to digitize Doctor-MR interaction through iPAD’s and interactive content. ➢ Launch of world-class SalesForce platform in iPAD’s for India field force to get consistency in execution to drive customer conversion. Salesforce
Slide 12: US Generics market stabilizing…
US Generics market stabilizing… Revenue- Q2 FY24 Revenue – Last 5 years INR Bn INR Bn 4.44 CAGR - 5% 4.18 Growth 6% 21.63 19.76 16.66 15.72 12.88 Q2FY23 Q2FY24 FY19 FY20 FY21 FY22 FY23 Approved ANDAs Injectable 10 Inhalation Derma 25 2 ➢Well-established US front end with strong customer base ➢3 prod
Slide 13: …ex-US market showing robust growth…
…ex-US market showing robust growth… Revenue – Q2 FY24 Revenue – Last 5 years INR Bn 2.52 INR Bn 2.15 Growth 17% CAGR: 15% 8.52 7.79 7.75 Q2FY23 Q2FY24 ➢Recorded 17% growth led by robust demand across markets 4.94 4.97 ➢Ex-US driven by partnership ➢Presence in following key markets - Europe, Canada,
Slide 14: …and API market rising steadily
…and API market rising steadily Revenue – Q2 FY24 Revenue – Last 5 years INR Bn INR Bn 3.22 2.94 Growth 10% CAGR: 11% 11.66 9.55 9.39 Q2FY23 Q2FY24 7.71 7.08 ➢Growth of 10% on YoY basis is led by high off-take and better product mix in Q2 ➢1 US DMF filed in Q2FY24. 132 Cumulative DMF filings with th
Slide 15: R&D investments set to decline
R&D investments set to decline Dosage form wise ANDA approval and Launch R&D Capabilities Q2FY24 H1 FY24 Dosage Forms Formulation : Vadodara and Hyderabad Approval* Launch Approval Launch OSD 4 2 6 4 API : Vadodara and Hyderabad Injectable - Gen 0 0 2 1 Bio Centre : Vadodara Injectable - Onco 0 0 0
Slide 16: Yearly Financials
Yearly Financials Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 16.31 56.53 11.78 53.93 53.06 46.06 12.13 10.53 # 8.29 7.79 # 6.65 # 4.97 # FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 EBIDTA margin % Capex INR Bn ROCE % 41* 30 26 6.97 6.87 32 * 20 # 4.67 25*# 4.12 14 # 14*# FY20 FY2
Slide 17: Enhancing ESG compliance
Sustainability Enhancing ESG compliance Targets: 19% Reduction in Indirect Energy Consumption 28% Reduction in Water Consumption(KL/MT) ➢ Net-Zero by 2040 16% Reduction (YoY) in Total GHG Emissions (Scope 1&2)(TCO2) ➢ Water Neutrality by 2027 21% Reduction in Hazardous Waste (MT/MT of Production) ➢
Slide 18: Strategic Roadmap
Strategic Roadmap Business Initiatives in FY23 Plan for FY24 • Create new marketing division for increasing • Strengthened the presence in sales volumes from high-growth therapies specialty therapies with the launch of • Introduce Data Analytics into onfield The India Business novel products operati
Slide 19: Company Overview
Company Overview
Slide 20: Company at a Glance
Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,30,000 Team size Field Force 14,500 + 5,000 + Brands Manufacturing facilities 9 185 ANDA filings Net Zero 252 (Sep 30, 2023) 2040 R&D Centres Products in US 2 125 +
Slide 21: Value Proposition
Value Proposition Developing Supplying APIs Ranks 20th in the specialty drug to 60+ countries Indian formulations pipeline for India globally market Exploring Consistent and Established a opportunities in High Dividend presence in Chile Injectables Payout & UAE Strengthening presence Expanding in Ca
Slide 22: The Journey
The Journey 1907 2007 2008 2009 2010 2012 2006 Acquired Dabur’s FDA approved Pharmaceutical Established by FDA approved FDA approved APIIndian Cardiology, facility FDA approved Multiple divisions to business demerged Formed a JV, Amin Family GI and Gynecology Formulation address chronic API facility
Slide 23: Robust Infrastructure
Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Mar’20 Oncology Oral Solids Jun’19 F2 – Panelav Oncology Injectables Oct’22 F2 - F3 - General Injectables Panelav Karkhadi F3 – Karkhadi Ophthalmic Mar’23 F4 – Jarod General Oral Solid
Slide 24: Thank you
For further queries, please contact: Mr. Ajay Desai ajay.desai@alembic.co.in 022-6695 3999 Mr. Mitanshu Shah mitanshu.shah@alembic.co.in 0265-663 7630 Thank you Investor Relations Advisors : Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactor
Alembic Pharmaceuticals — Q2 FY24 Earnings Presentation on 6ix